Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burfiralimab + Oral Antivirals in Chronic Hepatitis B
NCT05808335Phase 2Unknown
- Sponsor
- ImmuneMed Inc.
- Start
- Jan 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of burfiralimab in Chronic Hepatitis B (CHB) (4 arms), sponsored by ImmuneMed Inc. Primary endpoint: Change in HBsAg from baseline at 24 weeks. Status: unknown.
02
Drugs
burfiralimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05808335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808335.